A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Condition(s):Leukemia, Lymphocytic, Chronic, B-Cell; Chronic Lymphocytic Leukemia; Lymphoma, Small LymphocyticLast Updated:August 13, 2014Terminated